This article was originally published in The Rose Sheet
Executive SummaryFragrance division sales for the first nine months fell 1% to $579 mil. ($1=1.48 CHF) due to struggling fine fragrances, ingredients units, which offset "strong sales growth momentum" by consumer products, Geneva-based flavor and fragrance supplier reports Oct. 10. Firm's fine fragrance business was hurt by general market slowdown, with shortfall "spread proportionally across all clients and brands." Fragrance ingredients "continued to suffer from sustained price pressure on commodities, a further decrease of cosmetic ingredient sales and lower levels of sales to fine fragrance producers," firm says. Including full-year sales from recently acquired Nestle flavor business, pro forma consolidated revenues increased a slight .8% to $1.46 bil...
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.